Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis = Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis

다국어 초록 (Multilingual Abstract)

Background/Aims: Studies have shown that nucleos(t)ide analogue (NA) treatment can reduce the risk of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients, but it is unclear which NA is most effective. We performed a meta-analysis and systematic review comparing the efficacies of NAs in CHB patients. Methods: We searched literature databases for randomized controlled trials (RCTs) and observational studies that analyzed the hepatic biochemical response, virological response, seroconversion rate, drug resistance rate, and HCC incidence rate in CHB patients treated with NAs. Meta-analyses were performed with RevMan and Stata/SE software. Results: Twelve cohort studies and one RCT were selected, in which entecavir (ETV), lamivudine (LAM), telbivudine (LdT), and/or tenofovir disoproxil fumarate (TDF) were evaluated in CHB patients. The meta-analysis showed that ETV was superior to LAM with regard to the HCC incidence (p<0.001), biochemical response (p=0.001), virological response (p=0.02), and drug resistance (p<0.001), and ETV was superior to LdT with regard to the virological response (p<0.001) and drug resistance (p<0.001). We found no significant difference between ETV and TDF with regard to the HCC incidence (p=0.08), biochemical response (p=0.39), virological response (p=0.31), serological conversion (p=0.38), or drug resistance (p=0.95). NA-treated patients with pre-existing cirrhosis had a 5.49 times greater incidence of HCC than those without cirrhosis (p<0.001). Conclusions: ETV or TDF should be used for long-term first-line monotherapy in CHB patients according to the current guidelines. Standardized protocols are needed for future studies of ETV and TDF to facilitate conclusive comparisons. Patients with cirrhosis are at significantly elevated risk for HCC, despite the benefits of NA treatment. (Gut Liver 2020;14:232-247)

참고문헌 (Reference)

1 Terrault NA, "Update on prevention, diagnosis, and treatment of chronic hepatitis B : AASLD 2018hepatitis B guidance" 67 : 1560-1599, 2018

2 Cui Y, "Update on epidemiology of hepatitis B and C in China" 28 (28): 7-10, 2013

3 Zeng X, "The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline : a systematic review" 8 : 2-10, 2015

4 Coffin CS, "The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy" 40 : 1262-1269, 2014

5 Venook AP, "The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective" 15 (15): 5-13, 2010

6 Flemming JA, "Tenofovir vs entecavir for hepatocellular carcinoma prevention in patients with chronic hepatitis B : one of these things is not like the other" 5 : 17-18, 2019

7 Woo G, "Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B : a systematic review and Bayesian meta-analyses" 139 : 1218-1229, 2010

8 Ogawa E, "Tenofovir alafenamide in the treatment of chronic hepatitis B : design, development, and place in therapy" 11 : 3197-3204, 2017

9 Scott LJ, "Tenofovir alafenamide : a review in chronic hepatitis B" 77 : 1017-1028, 2017

10 An J, "Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA : a randomized trial" 17 : 15-, 2017

11 손원, "Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B" 대한간학회 23 (23): 170-178, 2017

12 Choi J, "Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B : a Korean nationwide cohort study" 5 : 30-36, 2019

13 Papatheodoridis GV, "Risk of hepatocellular carcinoma in chronic hepatitis B : assessment and modification with current antiviral therapy" 62 : 956-967, 2015

14 Wong DK, "Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency" 11 : 1004-1010, 2013

15 Lee JH, "Prior exposure to lamivudine increases entecavir resistance risk in chronic hepatitis B Patients without detectable lamivudine resistance" 58 : 1730-1737, 2014

16 Lai CL, "Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy" 57 : 399-408, 2013

17 Wong GL, "Oral nucleos(t)ide analogues reduce recurrence and death in chronic hepatitis B-related hepatocellular carcinoma" 43 : 802-813, 2016

18 Wang JP, "Nucleos(t)ide analogues associated with a reduced risk of hepatocellular carcinoma in hepatitis B patients : a population-based cohort study" 121 : 1446-1455, 2015

19 Lim YS, "Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine" 147 : 152-161, 2014

20 Kim BG, "Mortality, liver transplantation and hepatic complications in patients with treatment-naïve chronic hepatitis B treated with entecavir vs tenofovir" 25 : 1565-1575, 2018

21 Buti M, "Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B" 51 : 640-646, 2009

22 Sung JJ, "Meta-analysis : treatment of hepatitis B infection reduces risk of hepatocellular carcinoma" 28 : 1067-1077, 2008

23 Levrero M, "Mechanisms of HBV-induced hepatocellular carcinoma" 64 (64): S84-S101, 2016

24 Wong GL, "Longterm use of oral nucleos(t)ide analogues for chronic hepatitis B does not increase cancer risk : a cohort study of 44 494 subjects" 45 : 1213-1224, 2017

25 Tsai MC, "Long-term outcomes of hepatitis B virus-related cirrhosis treated with nucleos(t)ide analogs" 116 : 512-521, 2017

26 Niro GA, "Long-term outcome of hepatitis B virus-related chronic hepatitis under protracted nucleos(t)ide analogues" 20 : 502-509, 2013

27 Kobashi H, "Long-term outcome and hepatocellular carcinoma development in chronic hepatitis B or cirrhosis patients after nucleoside analog treatment with entecavir or lamivudine" 41 : 405-416, 2011

28 Xu B, "Long-term lamivudine treatment achieves regression of advanced liver fibrosis/cirrhosis in patients with chronic hepatitis B" 30 : 372-378, 2015

29 Lingala S, "Long-term lamivudine therapy in chronic hepatitis B" 44 : 380-389, 2016

30 Hosaka T, "Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection" 58 : 98-107, 2013

31 Idilman R, "Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting" 22 : 504-510, 2015

32 Köklü S, "Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis" 11 : 88-94, 2013

33 Liaw YF, "Lamivudine for patients with chronic hepatitis B and advanced liver disease" 351 : 1521-1531, 2004

34 Jayakumar R, "Laboratory evaluation of three regimens of treatment of chronic hepatitis B : tenofovir, entecavir and combination of lamivudine and adefovir" 4 : 10-16, 2012

35 Schoggins JW, "Interferon-stimulated genes and their antiviral effector functions" 1 : 519-525, 2011

36 Papatheodoridis GV, "Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir : HepNet. Greece cohort" 22 : 120-127, 2015

37 Honda M, "Hepatitis B virus(HBV)core-related antigen during nucleos(t)ide analog therapy is related to intra-hepatic HBV replication and development of hepatocellular carcinoma" 213 : 1096-1106, 2016

38 Clark DN, "Hepatitis B virus reverse transcriptase : target of current antiviral therapy and future drug development" 123 : 132-137, 2015

39 Nassal M, "HBV cccDNA : viral persistence reservoir and key obstacle for a cure of chronic hepatitis B" 64 : 1972-1984, 2015

40 Ozakyol A, "Global epidemiology of hepatocellular carcinoma(HCC epidemiology)" 48 : 238-240, 2017

41 Torre LA, "Global cancer statistics, 2012" 65 : 87-108, 2015

42 Kew MC, "Epidemiology of hepatocellular carcinoma in sub-Saharan Africa" 12 : 173-182, 2013

43 Li W, "Efficacy of entecavir-based rescue therapy in lamivudine-resistant chronic hepatitis B patients in China : a retrospective study" 73 : 223-247, 2018

44 Riveiro-Barciela M, "Effectiveness and safety of entecavir or tenofovir in a Spanish cohort of chronic hepatitis B patients : validation of the Page-B score to predict hepatocellular carcinoma" 62 : 784-793, 2017

45 Yin J, "Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma : a two-stage longitudinal clinical study" 31 : 3647-3655, 2013

46 European Association for the Study of the Liver, "EASL clinical practice guidelines : management of chronic hepatitis B virus infection" 57 : 167-185, 2012

47 Hsu YC, "Determinants of hepatocellular carcinoma in cirrhotic patients treated with nucleos(t)ide analogues for chronic hepatitis B" 69 : 1920-1927, 2014

48 Lo AO, "Current developments in nucleoside/nucleotide analogues for hepatitis B" 8 : 607-622, 2014

49 Stang A, "Critical evaluation of the Newcastle-Ottawa Scale for the assessment of the quality of nonrandomized studies in metaanalyses" 25 : 603-605, 2010

50 Tang LSY, "Chronic hepatitis B infection : a review" 319 : 1802-1813, 2018

51 Chen W, "Cancer statistics in China, 2015" 66 : 115-132, 2016

52 Centers for Disease Control and Prevention, "CDC Health Information for International Travel 2014: The Yellow Book" Oxford University Press 2013

53 Wu CY, "Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B : a nationwide cohort study" 147 : 143-151, 2014

54 Jadad AR, "Assessing the quality of reports of randomized clinical trials : is blinding necessary" 17 : 1-12, 1996

55 Liaw YF, "Asian-Pacific consensus statement on the management of chronic hepatitis B : a 2012 update" 6 : 531-561, 2012

56 Sacks SL, "Antiviral treatment of chronic hepatitis B virus infection : pharmacokinetics and side effects of interferon and adenine arabinoside alone and in combination" 21 : 93-100, 1982

57 Thiele M, "Antiviral therapy for prevention of hepatocellular carcinoma and mortality in chronic hepatitis B : systematic review and meta-analysis" 3 : e003265-, 2013

58 Terrault NA, "AASLD guidelines for treatment of chronic hepatitis B" 63 : 261-283, 2016

59 Tsai MC, "A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B : a match-control study" 20 : O90-O100, 2014

60 Yao GB, "A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China" 10 : 131-137, 2009